At-home diagnostics startup Inito raises $29 million from BII, Fireside Ventures

At-home diagnostics startup Inito has raised $29 million in a Series B funding round led by Bertelsmann India Investments, with participation from existing investor Fireside Ventures.

The fundraise takes the startup's total equity capital raised to $45 million.

Inito entered the market in 2021 with its first fertility monitor designed to enable quantitative hormone diagnostics at home. The startup's flagship fertility monitor records a continuous dataset of hormone biomarkers, allowing users to measure FSH, Estrogen, LH and PdG, the urine metabolite of progesterone.

These measurements are processed by Inito’s AI models, which interpret hormone patterns to help users understand their bodies better.

After supporting tens of thousands of pregnancies at a scale comparable to the US IVF industry, the company is now expanding beyond fertility. It aims to build a broader at-home hormone and health diagnostics platform powered by AI-engineered antibodies.

“We have always believed that healthcare should start at home. Hormones shape fertility, mood, metabolism, sleep, and energy, yet reliable testing still relies on clinic infrastructure”, said Aayush Rai and Varun AV, co-founders of Inito.

“If you want to understand your hormones, you shouldn’t have to wait weeks for a lab report, you should be able to do it from home, with clinical-grade technology. AI-engineered antibodies allow us to build diagnostic tests that simply were not possible before.”

The startup said that conventional diagnostics depend on decades-old biological processes. Traditional antibodies are grown inside animals and screened manually in labs, a method that is slow, costly and difficult to control. These antibodies often lack the sensitivity required for accurate at-home testing across multiple biomarkers and can break down or vary from batch to batch.

Advances in computational protein design and machine-learning models now make it possible to predict how proteins fold and bind, enabling the development of synthetic antibodies that are more sensitive and consistent. This shift removes long-standing bottlenecks that have held back innovation in diagnostics.

“The future of healthcare lies at the intersection of deep science, AI, and personal wellness — and that’s exactly where Inito is leading,” said Swati Murarka, Principal at Bertelsmann India Investments.

“By combining clinical precision with intelligent design, Inito is redefining diagnostics for the modern world. At BII, we’re proud to back visionary founders building globally scalable innovation from India — and Inito exemplifies that ambition.”

“We have seen Inito evolve from a breakthrough idea into a trusted women’s health brand built on deep consumer insight and scientific accuracy. The team’s ability to deliver clinical-grade insights through a simple and accessible solution has earned strong consumer love. We are proud to reaffirm our partnership as they scale their impact globally” said Kannan Sitaram, Co-founder & Partner, Fireside Ventures.

With the fresh capital, Inito plans to accelerate its work on designing diagnostic tests in silico, replacing slow and inconsistent animal-based development methods.

Inito claims it currently holds more than 20 patents and operates with a growing global team across Dubai, Bengaluru and London. Alongside fertility, it is expanding into additional health areas such as testosterone, vitamins and thyroid function.